Minocycline
Amzeeq, Arestin, Emrosi, Minocin, Minocycline, Zilxi (minocycline) is a small molecule pharmaceutical. Minocycline was first approved as Minocin on 1982-01-01. It is used to treat acne vulgaris, anthrax, borrelia infections, chancroid, and cholera amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Amzeeq, Arestin, Emrosi, Minocin, Minocycline, Zilxi (discontinued: Dynacin, Minocin, Minocycline, Minolira, Solodyn, Ximino)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Minocycline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MINOCIN | Bausch Health Companies | N-050649 RX | 1990-05-31 | 2 products, RLD |
| AMZEEQ | Journey Medical | N-212379 RX | 2019-10-18 | 1 products, RLD, RS |
| ZILXI | Journey Medical | N-213690 RX | 2020-05-28 | 1 products, RLD, RS |
| EMROSI | Journey Medical | N-219015 RX | 2024-11-01 | 1 products, RLD, RS |
| ARESTIN | Orapharma | N-050781 RX | 2001-02-16 | 1 products, RLD, RS |
Show 7 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amzeeq | New Drug Application | 2023-10-01 |
| arestin | New Drug Application | 2024-05-31 |
| emrosi | New Drug Application | 2025-04-22 |
| minocin | New Drug Application | 2025-09-11 |
| minocycline hydrochloride | ANDA | 2026-04-22 |
| minolira extended release | New Drug Application | 2022-11-02 |
| solodyn | New Drug Application | 2011-04-04 |
| zilxi | New Drug Application | 2024-02-09 |
Indications
FDA
EMA
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Minocycline Hydrochloride, Amzeeq, Journey | |||
| 10398641 | 2037-09-08 | U-2647 | |
| 10849847 | 2037-09-08 | U-2647 | |
| 8865139 | 2030-10-01 | DP | U-1631, U-2647 |
| 8945516 | 2030-10-01 | DP | |
| 8992896 | 2030-10-01 | DP | U-1631, U-2647 |
| 9675700 | 2030-10-01 | DP | U-1631, U-2647 |
| 10086080 | 2030-10-01 | U-2647 | |
| 10137200 | 2030-10-01 | U-2647 | |
| 10213512 | 2030-10-01 | DP | U-1631, U-2647 |
| 10265404 | 2030-10-01 | DP | |
| 10517882 | 2030-10-01 | U-2647 | |
| 10821187 | 2030-10-01 | U-2647 | |
| Minocycline Hydrochloride, Minolira, Epi Hlth | |||
| 11103517 | 2036-04-07 | DP | |
| Minocycline Hydrochloride, Solodyn, Bausch | |||
| 9192615 | 2031-11-17 | DP | |
| 7541347 | 2027-04-02 | U-917 | |
| 7544373 | 2027-04-02 | DP | |
| 7919483 | 2027-03-07 | U-124, U-1078 | |
| 7790705 | 2025-06-24 | U-124, U-1078 | |
| 8252776 | 2025-06-24 | U-124 | |
| 8268804 | 2025-06-24 | U-124, U-1078 | |
| 8722650 | 2025-06-24 | U-1078 | |
| Minocycline Hydrochloride, Minocin, Rempex | |||
| 9084802 | 2031-05-12 | U-282 | |
| 9278105 | 2031-05-12 | U-282 | |
| Minocycline Hydrochloride, Zilxi, Journey | |||
| 10322186 | 2030-10-01 | U-1631 | |
| 10946101 | 2030-10-01 | U-1631 | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AB: Antiinfectives and antiseptics for local oral treatment
— A01AB23: Minocycline
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AF: Antiinfectives for treatment of acne
— D10AF07: Minocycline
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01A: Tetracycline antibiotics
— J01AA: Tetracyclines
— J01AA08: Minocycline
HCPCS
Code | Description |
|---|---|
| J2265 | Injection, minocycline hydrochloride, 1 mg |
Clinical
Clinical Trials
315 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 3 | 5 | 5 | 6 | 2 | 21 |
| Infections | D007239 | EFO_0000544 | — | — | 2 | 1 | 8 | 10 | 21 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | 2 | 2 | 6 | 6 | 4 | 18 |
| Depression | D003863 | — | F33.9 | 2 | 4 | 4 | 3 | 2 | 15 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | 3 | 6 | 3 | 14 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 2 | 2 | 4 | 3 | 2 | 13 |
| Rosacea | D012393 | — | L71 | 3 | 6 | 3 | 2 | — | 13 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 2 | 4 | 5 | 3 | 1 | 11 |
| Communicable diseases | D003141 | — | — | — | 1 | 1 | 3 | 5 | 10 |
| Ischemic stroke | D000083242 | — | — | 1 | 4 | 5 | 2 | 1 | 10 |
Show 40 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 2 | 1 | — | 3 | 7 |
| Cognitive dysfunction | D060825 | — | G31.84 | 4 | 3 | 2 | — | — | 7 |
| Cerebral hemorrhage | D002543 | — | — | 3 | 3 | 2 | — | 1 | 6 |
| Neuroinflammatory diseases | D000090862 | — | — | 2 | 1 | 2 | — | — | 5 |
| Sclerosis | D012598 | — | — | — | 2 | 3 | — | — | 5 |
| Pneumothorax | D011030 | — | J93.11 | — | 1 | 3 | — | 2 | 5 |
| Catheter-related infections | D055499 | — | — | — | — | 2 | — | 2 | 4 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 2 | 2 | — | — | 4 |
| Recurrence | D012008 | — | — | 1 | 1 | 1 | — | 1 | 3 |
| Colorectal neoplasms | D015179 | — | — | — | 2 | 1 | — | — | 3 |
Show 47 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | 4 | 4 | — | — | — | 5 |
| Head and neck neoplasms | D006258 | — | — | 1 | 3 | — | — | 1 | 4 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 3 | — | — | 1 | 4 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 3 | — | — | 1 | 4 |
| Fragile x syndrome | D005600 | — | Q99.2 | 1 | 1 | — | — | 2 | 4 |
| Macular edema | D008269 | — | — | 3 | 3 | — | — | 1 | 4 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | 3 | — | — | — | 3 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 3 | — | — | — | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 1 | — | — | — | 3 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 2 | 2 | — | — | — | 3 |
Show 65 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | 4 | 10 |
| Infectious skin diseases | D012874 | — | — | 1 | — | — | — | 1 | 2 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | 1 | — | — | — | 1 | 2 |
| Autism spectrum disorder | D000067877 | — | F84.0 | 2 | — | — | — | — | 2 |
| Cognition disorders | D003072 | — | — | 2 | — | — | — | — | 2 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | 1 | 2 |
| Acute kidney injury | D058186 | — | N17 | 1 | — | — | — | 1 | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 1 | — | — | — | — | 1 |
| Hemangioma | D006391 | — | D18.0 | 1 | — | — | — | — | 1 |
Show 23 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 2 | 2 |
| Infectious arthritis | D001170 | EFO_1001351 | M00 | — | — | — | — | 1 | 1 |
| Prosthesis-related infections | D016459 | EFO_1001406 | — | — | — | — | — | 1 | 1 |
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
| Granuloma | D006099 | — | — | — | — | — | — | 1 | 1 |
| Granuloma annulare | D016460 | — | L92.0 | — | — | — | — | 1 | 1 |
| Fasting | D005215 | EFO_0002756 | — | — | — | — | — | 1 | 1 |
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Minocycline |
| INN | minocycline |
| Description | Minocycline is a tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5. It has a role as an antibacterial drug, an Escherichia coli metabolite and a geroprotector. It is a member of tetracyclines, a tetracenomycin and a tertiary alpha-hydroxy ketone. It is a conjugate acid of a minocycline(1-). It is a tautomer of a minocycline zwitterion. |
| Classification | Small molecule |
| Drug class | antibiotics (tetracycline derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O |
Identifiers
| PDB | — |
| CAS-ID | 10118-90-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1434 |
| ChEBI ID | 50694 |
| PubChem CID | 54675783 |
| DrugBank | DB01017 |
| UNII ID | FYY3R43WGO (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zilxi – Fortress Biotech
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Zilxi – Journey Medical
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Emrosi – Journey Medical
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Minolira – Novan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Minocin – Melinta Therapeutics /new/
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Amzeeq – Fortress Biotech
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Amzeeq – Journey Medical
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Ximino – Fortress Biotech
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Ximino – Journey Medical
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Minocycline
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,930 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use